Shuyuan Yao, Allogene Overland CEO

Al­lo­gene, Over­land woo an ex­pe­ri­enced hand from WuXi to steer their al­lo­gene­ic CAR-T JV

Al­lo­gene Over­land Bio­pharm, the joint ven­ture David Chang and Ed Zhang set up to tur­bocharge the de­vel­op­ment of off-the-shelf CAR-T ther­a­pies in Chi­na, has locked in its first CEO.

Shuyuan Yao joins from WuXi Ad­vanced Ther­a­pies, the cell and gene ther­a­py-fo­cused arm of the sprawl­ing con­tract test­ing, de­vel­op­ment and man­u­fac­tur­ing group. Most re­cent­ly CSO, head of re­search and tech­nol­o­gy de­vel­op­ment, Yao was cred­it­ed for dri­ving the cre­ation of WuXi’s cell ther­a­py R&D busi­ness unit, and had led every­thing from tech ac­qui­si­tion and de­vel­op­ment to trans­la­tion and ap­pli­ca­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.